0001437749-24-009831.txt : 20240328 0001437749-24-009831.hdr.sgml : 20240328 20240328161841 ACCESSION NUMBER: 0001437749-24-009831 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240328 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240328 DATE AS OF CHANGE: 20240328 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pulse Biosciences, Inc. CENTRAL INDEX KEY: 0001625101 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 465696597 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37744 FILM NUMBER: 24799233 BUSINESS ADDRESS: STREET 1: 3957 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: 510-906-4600 MAIL ADDRESS: STREET 1: 3957 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 FORMER COMPANY: FORMER CONFORMED NAME: Electroblate, Inc. DATE OF NAME CHANGE: 20141113 8-K 1 plse20240327_8k.htm FORM 8-K plse20240327_8k.htm
false 0001625101 0001625101 2024-03-28 2024-03-28
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported): March 28, 2024
 
Pulse Biosciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)
     
Delaware
001-37744
46-5696597
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
 
3957 Point Eden Way 
Hayward, California 94545
(Address of Principal Executive Offices) (Zip Code)
 
510-906-4600
(Registrant’s Telephone Number, Including Area Code)
 
Not Applicable
(Former Name or Former Address, If Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common stock, $0.001 par value per share
PLSE
The Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 2.02
Results of Operations and Financial Condition.
 
On March 28, 2024, Pulse Biosciences, Inc. (the “Company”) announced its financial and operational results for the fiscal quarter and full year ended December 31, 2023. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.
 
This information, as well as Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
 
Item 8.01
Other Events.
 
On March 28, 2024, Pulse Biosciences, Inc. (the “Company”) issued a press release announcing plans to initiate a rights offering to its existing stockholders of record as of the close of business on a record date in April to be announced as soon as practicable.
 
As approved by the Company’s Board of Directors, the rights offering of up to $60 million worth of units (“Units”) will be available to all holders of record of the Company’s common stock, par value $0.01 (the “Common Stock”) as of the close of the market on a record date in April to be announced as soon as practicable (the “Record Date”).  Each Unit will consist of one share of Common Stock and two warrants, each to purchase one-half of one share of Common Stock, with each warrant having different redemption provisions. The subscription price per Unit shall be equal to the lesser of (i) $10.00 per Unit (the “Initial Price”) and (ii) the volume weighted average price of the Company’s Common Stock for the ten trading day period through and including the expiration date of the offering, which has not yet been set by the Board. The subscription price will determine the final number of Units issuable, and subsequently the pro rata number of Units to which stockholders can subscribe. Each warrant will have a per share exercise price equal to 110% of the subscription price for the Units. The Company intends to distribute to all holders of Common Stock as of the Record Date non-transferable subscription rights to purchase Units at the price provided above.   
 
Assuming that the rights offering is fully subscribed at the Initial Price, the Company will receive gross proceeds of up to $60 million, less expenses related to the rights offering, and upon exercise of all of the warrants, would receive additional proceeds of up to $66 million.  The rights offering will include an over-subscription right to permit each rights holder that exercises its basic subscription rights in full to purchase additional Units that remain unsubscribed at the expiration of the offering. The availability of the over-subscription right will be subject to certain terms and conditions to be set forth in the offering documents. 
 
Robert Duggan, the Company’s Executive Chairman and majority stockholder, has indicated his support for the rights offering and his intent to participate in the rights offering on the same terms as all other investors. 
 
The Company intends to register the rights offering with the Securities and Exchange Commission (the “SEC”) by filing a prospectus on Form S-3. When available, a copy of the prospectus may be obtained at the website maintained by the SEC at www.sec.gov.  This Current Report on Form 8-K does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The rights offering will be made pursuant to a registration statement on Form S-3 containing the detailed terms of the rights offering to be filed with the SEC. Any offer will be made only by means of a prospectus forming part of the registration statement.
 
Item 9.01
Financial Statements and Exhibits.
 
(d) Exhibits
 
Exhibit
Number
Description
   
99.1
99.2 Press Release issued by Pulse Biosciences, Inc. dated March 28, 2024 - Rights Offering
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
PULSE BIOSCIENCES, INC.
  
     
     
Date: March 28, 2024
By:
/s/ Kevin P. Danahy
  
   
Kevin P. Danahy
  
   
President and Chief Executive Officer
(Principal Executive and Principal Financial Officer)
  
 
 
 EX-99.1 2 ex_646620.htm PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED MARCH 28, 2024 - FINANCIAL RESULTS ex_646620.htm

Exhibit 99.1

 

 

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results

 

HAYWARD, Calif. [Business Wire] – March 28, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2023.

 

Recent Business Highlights

 

CellFX nsPFA Percutaneous Electrode (End-effector of the proprietary designed and engineered CellFX nsPFA energy delivery system)

 

●

Received U.S. FDA 510(k) clearance for use in non-cardiac soft tissue ablation.
 

●

Completed enrollment in the 30-patient first-in-human clinical trial on the treatment of benign thyroid nodules and principal investigator Dr. Stefano Spiezia presented the groundbreaking positive clinical data at the North American Society for Interventional Thyroidology 2024.

 

CellFX nsPFA 360° Cardiac Catheter (End-effector of the proprietary designed and engineered CellFX nsPFA energy delivery system)

 

●

Completed 60-Day post-procedure evaluations of the initial patients treated in the catheter first-in-human feasibility study; the remaps demonstrated exceptional lesion quality, exceeding clinicians' expectations.
 

●

Dr. Vivek Reddy showcased the first-in-human cases in a podium presentation at the 29th Annual AF Symposium which was well received by colleagues in the audience.

 

CellFX nsPFA Cardiac Clamp (End-effector of the proprietary designed and engineered CellFX nsPFA energy delivery system)

 

●

Filed FDA 510(k) submission in December 2023, and is continuing discussions with FDA.

 

Announcement of Rights Offering & Universal Shelf Filing

 

●

The Company’s Board of Directors has approved plans to initiate a rights offering, pending U.S. Securities and Exchange Commission (SEC) approval of a registration statement that is expected to be filed next week, as detailed in the Company’s press release issued earlier today titled, Pulse Biosciences Announces Plans to Initiate a Rights Offering
 

●

Consistent with the Company’s prior rights offerings, the units of stock and warrants will only be offered to existing stockholders as of a predetermined and to be announced record date, to be announced once the registration statement becomes effective. Additional details on the rights offering can be found in the Company’s press release issued earlier today.
 

●

To fund its future operations, the Company has filed a preliminary registration statement with the SEC to establish a universal shelf pursuant to which, once it is effective, the Company may, from time to time, sell up to an aggregate of $50 million worth of its common stock, preferred stock, depositary shares, warrants, debt securities, or units over the three year life of the universal shelf.

 

“In 2023 the Pulse Biosciences team executed on the development of our portfolio of CellFX nsPFA devices. This progress has led to significant milestones like the FDA clearance of the CellFX nsPFA Percutaneous Electrode System, exceptional clinical results in the 60 day remaps of our first patients treated in the CellFX nsPFA 360° Cardiac Catheter first-in-human feasibility study, and the 510(k) submission of our CellFX nsPFA Cardiac Clamp,” said Kevin Danahy, President and Chief Executive Officer of Pulse Biosciences.

 

Fourth Quarter 2023 Financial Results

Total GAAP costs and expenses, representing cost of revenues, research and development, sales and marketing, and general and administrative expenses, for the three months ended December 31, 2023, were $12.5 million compared to $8.7 million for the prior year period. The increase in GAAP costs and expenses was primarily driven by an increase in non-cash stock-based compensation expense which was $3.3 million for the three months ended December 31, 2023 compared to $0.7 million for the prior year period. The remaining increase in costs and expenses compared to the prior year was driven by an increase in research and development expenses to support the development of the CellFX nsPFA product portfolio. Non-GAAP costs and expenses for the three months ended December 31, 2023, were $8.9 million compared to $7.7 million for the prior year period.

 

GAAP net loss for the three months ended December 31, 2023 was ($11.9) million compared to ($9.2) million for the three months ended December 31, 2022. Non-GAAP net loss for the three months ended December 31, 2023 was ($8.3) million compared to ($8.1) million for the three months ended December 31, 2022.

 

Full Year 2023 Financial Results

Total GAAP costs and expenses, representing cost of revenues, research and development, sales and marketing and general and administrative expenses, for the full year of 2023 were $43.6 million, compared to $58.8 million in 2022. Non-GAAP costs and expenses for the full year of 2023 were $35.1 million compared to $51.3 million in the prior year. The decrease in costs and expenses compared to the prior year period was primarily driven by optimizing headcount and streamlining and focusing resources on advancing the development of the CellFX nsPFA product portfolio. 

 

GAAP net loss for the full year of 2023 was ($42.2) million compared to ($58.5) million for 2022. Non-GAAP net loss for 2023 was ($33.8) million compared to ($51.1) million in 2022.

 

Cash and cash equivalents totaled $44.4 million as of December 31, 2023, compared to $61.1 million as of December 31, 2022 and $50.4 million as of September 30, 2023. Cash used in the fourth quarter of 2023 was $6.9 million compared to $8.0 million in the same period in the prior year and $8.7 million used in the third quarter of 2023. Excluding net proceeds from financing, cash used in the full year of 2023 totaled $32.8 compared to $47.3 million used in 2022.

 

Reconciliations of GAAP to non-GAAP cost and expenses and net loss have been provided in the tables following the financial statements in this press release. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures.”

 

 
 

 

Webcast and Conference Call Information

Pulse Biosciences’ management will host a conference call today, March 28, 2024, beginning at 1:30pm PT. Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. A live and recorded webcast of the event will be available at https://investors.pulsebiosciences.com/.

 

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.

 

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

 

Non-GAAP Financial Measures

In this press release, in order to supplement the Company’s condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for the statement of operations. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results in order to supplement investors’ and other readers’ understanding and assessment of the Company’s financial performance. Company management uses these measurements as aids in monitoring the Company’s ongoing financial performance from quarter to quarter, and year to year, on a regular basis and for financial and operational decision-making. Non-GAAP adjustments include stock-based compensation, depreciation and amortization and restructuring charges. From time to time in the future, there may be other items that the Company may exclude if the Company believes that doing so is consistent with the goal of providing useful information to management and investors. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. Investors are cautioned that there are a number of limitations associated with the use of non-GAAP financial measures as analytical tools. Investors are encouraged to review these reconciliations, and not to rely on any single financial measure to evaluate the Company’s business.

 

Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies, which could reduce the usefulness of the Company’s non-GAAP financial measures as tools for comparison. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. Non-GAAP financial measures in this earnings release exclude the following:

 

Non-cash expenses for stock-based compensation.  The Company has excluded the effect of stock-based compensation expenses in calculating the Company’s non-GAAP cost and expenses and net loss measures. Although stock-based compensation is a key incentive offered to employees, the Company continues to evaluate its business performance excluding stock-based compensation expenses. The Company records stock-based compensation expense related to grants of time-based and performance-based options, such as options that vest as a result of the Company’s market capitalization. Depending upon the size, timing and terms of the grants, as well as the probability of achievement of performance-based awards, this expense may vary significantly but will recur in future periods. The Company believes that excluding stock-based compensation better allows for comparisons from period to period.

 

Depreciation and amortization.  The Company has excluded depreciation and amortization expense in calculating its non-GAAP cost and expenses and net loss measures. Depreciation and amortization are non-cash charges to current operations.

 

Restructuring charges.  The Company has excluded restructuring charges in calculating its non-GAAP cost and expenses and net loss measures. Restructuring programs involve discrete initiatives designed to improve operating efficiencies and include employee termination, contract termination, and other exit costs associated with the restructuring program. The Company believes that excluding discrete restructuring charges allows for better comparisons from period to period.

 

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company’s CellFX nsPFA technology and CellFX System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning the Company’s expected product development efforts and plans to sell products commercially, such as its plans to demonstrate advantages of its CellFX nsPFA Percutaneous Electrode over current treatment options, statements concerning the Company’s future fundraising efforts and whether those efforts will allow the Company to continue current operations as planned, statements concerning market opportunities, customer adoption and future use of the CellFX System to address a range of conditions such as atrial fibrillation, statements concerning early clinical successes and whether they are predictive of the safety and efficacy of any medical device such as the CellFX nsPFA 360° Cardiac Catheter, Pulse Biosciences’ expectations, whether stated or implied, regarding whether the Company’s CellFX nsPFA technology will become a disruptive and durable treatment option for treating atrial fibrillation or any other medical condition, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

 

Investor Contacts:

Pulse Biosciences

Kevin Danahy, President and CEO

510.241.1077

IR@pulsebiosciences.com

 

or
Gilmartin Group
Philip Trip Taylor

415.937.5406
philip@gilmartinir.com

 

 
 

 

PULSE BIOSCIENCES, INC.

Condensed Consolidated Balance Sheets

(In thousands, except per share amounts)

(Unaudited)

 

   

December 31,

    

December 31,

  
   

2023

    

2022

  

ASSETS

                

Current assets:

                

Cash and cash equivalents

   $ 44,365     $ 61,139  

Prepaid expenses and other current assets

     963       1,008  

Total current assets

     45,328       62,147  
                 

Property and equipment, net

     1,528       1,961  

Intangible assets, net

     1,886       2,551  

Goodwill

     2,791       2,791  

Right-of-use assets

     7,256       8,062  

Other assets

     365       365  

Total assets

   $ 59,154     $ 77,877  
                 

LIABILITIES AND STOCKHOLDERS’ EQUITY

                

Current liabilities:

                

Accounts payable

   $ 1,836     $ 1,573  

Accrued expenses

     3,814       2,595  

Lease liability, current

     1,058       896  

Related party note payable, current

     —       917  

Total current liabilities

     6,708       5,981  
                 

Lease liability, less current

     8,086       9,144  

Related party note payable, less current

     —       65,000  

Total liabilities

     14,794       80,125  
                 

Stockholders’ equity:

                

Preferred stock, $0.001 par value;
authorized – 50,000 shares; no shares issued and outstanding

     —       —  

Common stock, $0.001 par value:
authorized – 500,000 shares; issued and outstanding – 55,144 shares and 37,235 shares at December 31, 2023 and December 31, 2022, respectively

     55       37  

Additional paid-in capital

     381,220       292,420  

Accumulated other comprehensive income (loss)

     —       —  

Accumulated deficit

     (336,915 )     (294,705 )

Total stockholders’ equity (deficit)

     44,360       (2,248 )

Total liabilities and stockholders’ equity

   $ 59,154     $ 77,877  

 

 
 

 

PULSE BIOSCIENCES, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share amounts)

(Unaudited)

 

   

Three-Month Periods Ended

    

Twelve-Month Periods Ended

  
   

December 31,

    

December 31,

  
   

2023

    

2022

    

2023

    

2022

  

Revenues:

                                

Product revenues

   $ —     $ (9 )   $ —     $ 700  

Total revenues

     —       (9 )     —       700  

Cost and expenses:

                                

Cost of revenues

     —       1,291       —       11,944  

Research and development

     7,799       4,095       27,797       20,839  

Sales and marketing

     —       768       —       12,019  

General and administrative

     4,734       2,582       15,777       13,955  

Total cost and expenses

     12,533       8,736       43,574       58,757  

Loss from operations

     (12,533 )     (8,745 )     (43,574 )     (58,057 )

Other income (expense):

                                

Interest income (expense), net

     600       (452 )     1,364       (448 )

Total other income (expense)

     600       (452 )     1,364       (448 )

Net loss

     (11,933 )     (9,197 )     (42,210 )     (58,505 )

Other comprehensive gain:

                                

Unrealized gain on available-for-sale securities

     —       —       —       —  

Comprehensive loss

   $ (11,933 )   $ (9,197 )   $ (42,210 )   $ (58,505 )

Net loss per share:

                                

Basic and diluted net loss per share

   $ (0.22 )   $ (0.25 )   $ (0.88 )   $ (1.72 )

Weighted average shares used to compute net loss per common share — basic and diluted

     55,058       37,229       48,038       33,935  

 

 

   

Three-Month Periods Ended

     Twelve-Month Periods Ended  
   

December 31,

     December 31,  

Stock Based Compensation Expense:

  

2023

    

2022

    

2023

    

2022

  

Cost of revenues

   $ —     $ 13     $ —     $ 217  

Research and development

     1,733       323       3,491       1,563  

Sales and marketing

     —       (39 )     —       733  

General and administrative

     1,611       451       3,690       2,678  

Total stock-based compensation expense

   $ 3,344     $ 748     $ 7,181     $ 5,191  
                                 
                                 
                                 

*For the three and twelve month periods ended December 31, 2023, the Company reclassified certain expenses as a result of the shift in focus from dermatology to cardiology. Expenses previously included in Cost of Revenues are now recorded as a part of Research and Development, and expenses previously included in Sales and Marketing are now recorded as a part of General and Administrative.

 
 

 

 

 

 
 

 

PULSE BIOSCIENCES, INC.

Consolidated Revenue Financial Highlights

(In thousands)

(Unaudited)

 

   

Three-Month Periods Ended

    

Twelve-Month Periods Ended

  
   

December 31,

    

December 31,

  
   

2023

   

2022

   

2023

   

2022

 

Revenue by category:

                                                                

Systems

   $ —       0 %   $ (16 )     0 %   $ —       0 %   $ 560       80 %

Cycle units

     —       0 %     7       0 %     —       0 %     140       20 %

Total revenue

   $ —       0 %   $ (9 )     -     $ —       0 %   $ 700       100 %
                                                                 

Revenue by geography:

                                                          

North America

   $ —       0 %   $ (9 )     0 %   $ —       0 %   $ 517       74 %

Rest of World

     —       0 %     —       0 %     —       0 %     183       26 %

Total revenue

   $ —       0 %   $ (9 )     -     $ —       0 %   $ 700       100 %

 

 
 

 

Reconciliation of GAAP to Non-GAAP Financial Measures

The following table presents the reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures:

(In thousands)

(Unaudited)

 

   

Three-Month Periods Ended

    

Twelve-Month Periods Ended

  
   

December 31,

    

December 31,

  
   

2023

   

2022

   

2023

   

2022

 

Reconciliation of GAAP to non-GAAP Cost of revenues:

                                

GAAP Cost of revenues

   $ —     $ 1,291     $ —     $ 11,944  

Less: Stock-based compensation expense

     —       (13 )     —       (217 )

Less: Depreciation and amortization

     —       (3 )     —       (18 )

Less: Restructuring

     —       —       —       (43 )

Non-GAAP Cost of revenues

   $ —     $ 1,275     $ —     $ 11,666  
                                 

Reconciliation of GAAP to non-GAAP Research and development:

                                

GAAP Research and development

   $ 7,799     $ 4,095     $ 27,797     $ 20,839  

Less: Stock-based compensation expense

     (1,733 )     (323 )     (3,491 )     (1,563 )

Less: Depreciation and amortization

     (54 )     (78 )     (226 )     (281 )

Less: Restructuring

     —       —       (38 )     (177 )

Non-GAAP Research and development

   $ 6,012     $ 3,694     $ 24,042     $ 18,818  
                                 

Reconciliation of GAAP to non-GAAP Sales and marketing:

                                

GAAP Sales and marketing

   $ —     $ 768     $ —     $ 12,019  

Less: Stock-based compensation expense

     —       39       —       (733 )

Less: Depreciation and amortization

     —       (10 )     —       (53 )

Less: Restructuring

     —       —       —       (598 )

Non-GAAP Sales and marketing

   $ —     $ 797     $ —     $ 10,635  
                                 

Reconciliation of GAAP to non-GAAP General and administrative:

                                

GAAP General and administrative

   $ 4,734     $ 2,582     $ 15,777     $ 13,955  

Less: Stock-based compensation expense

     (1,611 )     (451 )     (3,690 )     (2,678 )

Less: Depreciation and amortization

     (250 )     (245 )     (980 )     (1,003 )

Less: Restructuring

     —       —       (5 )     (60 )

Non-GAAP General and administrative

   $ 2,873     $ 1,886     $ 11,102     $ 10,214  
                                 

Reconciliation of GAAP to non-GAAP Cost and expenses:

                                

GAAP Cost and expenses

   $ 12,533     $ 8,736     $ 43,574     $ 58,757  

Less: Stock-based compensation expense

     (3,344 )     (748 )     (7,181 )     (5,191 )

Less: Depreciation and amortization

     (304 )     (336 )     (1,206 )     (1,355 )

Less: Restructuring

     —       —       (43 )     (878 )

Non-GAAP Cost and expenses

   $ 8,885     $ 7,652     $ 35,144     $ 51,333  
                                 

Reconciliation of GAAP to non-GAAP Net loss:

                                

GAAP Net loss

   $ (11,933 )   $ (9,197 )   $ (42,210 )   $ (58,505 )

Add: Stock-based compensation expense

     3,344       748       7,181       5,191  

Add: Depreciation and amortization

     304       336       1,206       1,355  

Add: Restructuring

     —       —       43       878  

Non-GAAP Net loss

   $ (8,285 )   $ (8,113 )   $ (33,780 )   $ (51,081 )

 

 

 
 EX-99.2 3 ex_646625.htm PRESS RELEASE ISSUED BY PULSE BIOSCIENCES, INC. DATED MARCH 28, 2024 - RIGHTS OFFERING HTML Editor

Exhibit 99.2

 

Pulse Biosciences Announces Plans to Initiate a Rights Offering

 

HAYWARD, Calif. [Business Wire] – March 28, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its Board of Directors has unanimously approved plans to initiate a rights offering.

 

The rights offering of up to $60 million worth of units (“Units”) will be available to all holders of record of the Company’s common stock, par value $0.01 (the “Common Stock”) as of the close of the market on a record date in April to be announced as soon as practicable (the “Record Date”).  Each Unit will consist of one share of Common Stock and warrants to purchase a total of one share of Common Stock, with each warrant having different redemption provisions. The subscription price per Unit shall be equal to the lesser of (i) $10.00 per Unit (the “Initial Price”) or (ii) the volume weighted average price of the Company’s Common Stock over the 10 trading days prior to the expiration date of the offering. The subscription price will determine the final number of Units issuable, and subsequently the pro rata number of Units to which stockholders can subscribe. Each warrant will have a per share exercise price equal to 110% of the subscription price for the Units. The Company intends to distribute to all holders of Common Stock as of the Record Date non-transferable subscription rights to purchase Units at the price provided above.   

 

Assuming that the rights offering is fully subscribed at the Initial Price, the Company will receive gross proceeds of up to $60 million, less expenses related to the rights offering, and upon exercise of all of the warrants, would receive additional proceeds of up to $66 million.  The rights offering will include an over-subscription right to permit each rights holder that exercises its basic subscription rights in full to purchase additional Units that remain unsubscribed at the expiration of the offering. The availability of the over-subscription right will be subject to certain terms and conditions to be set forth in the offering documents. 

 

Robert Duggan, the Company’s Executive Chairman and majority stockholder, has indicated his support for the rights offering and his intent to participate in the rights offering on the same terms as all other investors. 

 

The Company intends to register the rights offering with the Securities and Exchange Commission (the “SEC”) by filing a prospectus on Form S-3. When available, a copy of the prospectus may be obtained at the website maintained by the SEC at www.sec.gov.  This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The rights offering will be made pursuant to a registration statement on Form S-3 containing the detailed terms of the rights offering to be filed with the SEC. Any offer will be made only by means of a prospectus forming part of the registration statement.

 

About Pulse Biosciences®

 

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.

 

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

 

Forward-Looking Statements

 

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company’s CellFX nsPFA technology and CellFX System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning the Company’s future fundraising efforts and whether those efforts will allow the Company to continue current operations as planned, statements concerning market opportunities, customer adoption and future use of the CellFX System to address a range of conditions such as atrial fibrillation, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

 

Investor Contacts:

 

Pulse Biosciences

Kevin Danahy, President and CEO

510.241.1077

IR@pulsebiosciences.com

 

Or

 

Gilmartin Group
Philip Trip Taylor

415.937.5406
philip@gilmartinir.com

 
 EX-101.SCH 4 plse-20240328.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 5 plse-20240328_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 6 plse-20240328_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 7 plse-20240328_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Document And Entity Information
Mar. 28, 2024
Document Information [Line Items]  
Entity, Registrant Name Pulse Biosciences, Inc.
Document, Type 8-K
Document, Period End Date Mar. 28, 2024
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-37744
Entity, Tax Identification Number 46-5696597
Entity, Address, Address Line One 3957 Point Eden Way
Entity, Address, City or Town Hayward
Entity, Address, State or Province CA
Entity, Address, Postal Zip Code 94545
City Area Code 510
Local Phone Number 906-4600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock
Trading Symbol PLSE
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001625101
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.plse.com/20240328/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports plse-20240328.xsd plse-20240328_def.xml plse-20240328_lab.xml plse-20240328_pre.xml plse20240327_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "plse20240327_8k.htm": { "nsprefix": "plse", "nsuri": "http://www.plse.com/20240328", "dts": { "schema": { "local": [ "plse-20240328.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "definitionLink": { "local": [ "plse-20240328_def.xml" ] }, "labelLink": { "local": [ "plse-20240328_lab.xml" ] }, "presentationLink": { "local": [ "plse-20240328_pre.xml" ] }, "inline": { "local": [ "plse20240327_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 26, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.plse.com/20240328/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "plse20240327_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d20248K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "plse20240327_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.plse.com/20240328/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001437749-24-009831-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-009831-xbrl.zip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plse20240327_8k_htm.xml IDEA: XBRL DOCUMENT 0001625101 2024-03-28 2024-03-28 false 0001625101 8-K 2024-03-28 Pulse Biosciences, Inc. DE 001-37744 46-5696597 3957 Point Eden Way Hayward CA 94545 510 906-4600 false false false false Common stock PLSE NASDAQ false